A LAT1‐Compatible, Leadlike Tyrosine‐Naphthoquinone Conjugate With Anticancer Activity
Drug Development Research · 2026-04 · 87 (2)
DOI: 10.1002/ddr.70269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 01.04.2026. Verfasst von Austin Seymour und 14 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry, Chemistry, and Physics Department, Georgia Southern University, Statesboro, Georgia, USA. Hauptthemen laut MEDLINE: Naphthoquinones, Large Neutral Amino Acid-Transporter 1, Tyrosine, Antineoplastic Agents. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
A L‐type amino acid transporter 1 (LAT1)‐compatible, anticancer‐active tyrosine‐naphthoquinone (NQ) conjugate was successfully developed. The conjugate was designed to exploit LAT1 overexpression in cancers with the goal of achieving selective cytotoxicity for cancerous over noncancerous cells. The tyrosine‐NQ molecule was subjected to cell viability, imaging, docking and in silico pharmacological studies along with structure‐activity relationship (SAR) assessment. Cell viability investigations included IC 50 and substrate‐competition studies. Cells of cancerous (PC3) and noncancerous (HEK293) origin with high and minimal expressions of LAT1, respectively, were employed for biochemical investigations. The tyrosine‐NQ assembly showed significant cytotoxic selectivity toward PC3 over HEK293, with activity comparable to that of the parent molecule NQ and doxorubicin (DOX), an approved drug. Docking studies demonstrated that the conjugate is LAT1‐compatible as it interacts with key residues along the protein's transport pathway. Cell viability competition studies verify a LAT1‐facilitated uptake. SAR studies revealed that the conjugate's anticancer activity is due to its aryloxy‐naphthoquinone motif. In silico pharmacological investigations determined that the conjugate is leadlike and therefore, well‐suited for structural modifications for further drug development. Finally, imaging investigations showed that, with PC3, the conjugate caused drug‐induced stress‐responses in nuclear morphology. Overall, findings demonstrate that the tyrosine‐NQ conjugate is a promising lead for the design of LAT1‐targeting, NQ‐based chemotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochemistry, Chemistry, and Physics Department, Georgia Southern University, Statesboro, Georgia, USA.
- Biochemistry, Chemistry, and Physics Department, Science Center, Georgia Southern University, Savannah, Georgia, USA.
- Mathematical Sciences Department, University Hall, Georgia Southern University, Savannah, Georgia, USA.
- Statistical Consulting Unit (SCU), Department of Mathematical Sciences, Statesboro, Georgia, USA.
- Mathematical Sciences Department, Georgia Southern University, Statesboro, Georgia, USA.
ORCID-Profile: Karelle S Aiken
Förderung
- NCI NIH HHS
- NIH HHS
Zitieren
APA
Seymour, A., Peterson, C., Osafo, R., Ashimi, A. A., Williams, D., Echezabal, L., Carrier, C., Clarke, A., Padgett, C. W., Dela Cerna, M. V. C., Utic, Z., Wanduku, D., Shank, N., Aiken, K. S., & Kocerha, J. (2026). A LAT1‐Compatible, Leadlike Tyrosine‐Naphthoquinone Conjugate With Anticancer Activity. Drug Development Research, 87(2). https://doi.org/10.1002/ddr.70269
Vancouver
Seymour A, Peterson C, Osafo R, Ashimi AA, Williams D, Echezabal L, et al. A LAT1‐Compatible, Leadlike Tyrosine‐Naphthoquinone Conjugate With Anticancer Activity. Drug Development Research. 2026;87(2). doi:10.1002/ddr.70269
BibTeX
@article{Seymour2026,
author = {Seymour, Austin and Peterson, Christian and Osafo, Raymond and Ashimi, Abdullahi A and Williams, Dylan and Echezabal, Laura and Carrier, Chelsea and Clarke, Alysa and Padgett, Clifford W and Dela Cerna, Mark Vincent C and Utic, Zheni and Wanduku, Divine and Shank, Nathaniel and Aiken, Karelle S and Kocerha, Jannet},
title = {A LAT1‐Compatible, Leadlike Tyrosine‐Naphthoquinone Conjugate With Anticancer Activity},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {2},
doi = {10.1002/ddr.70269}
}
EUVIMED